Keimyung Med J.  2014 Dec;33(2):132-133. 10.0000/kmj.2014.33.2.132.

A Case of Patient with Lung Adenocarcinoma with Double Rare EGFR Mutation of G719C and L861Q

• Yun JT
• Kim GJ
• Kim SY
• Jeong JW
• Park SY
• Yang YJ
• Park JC

• KMID: 1967200
• DOI: http://doi.org/10.0000/kmj.2014.33.2.132

Abstract

The vast majority of epidermal growth factor receptor (EGFR) gene mutations are detected in lung adenocarcinoma. EGFR mutations are the strongest predictor of response to EGFR tyrosine kinase inhibitor (TKI) treatment in patient with advanced non-small cell lung cancer. Of these, exon 19 deletions and exon 21 L858R point mutations account for more than 80% of mutations detected in tumor with EGFR mutations, which called classical EGFR mutations, and double mutations mainly composed of classical and uncommon EGFR mutations are reported to be present in 13% of total EGFR mutations. But there has been no report to date of patient with double mutation of TKI sensitive uncommon EGFR mutations (G719C and L861Q). We experienced a case of patient with lung adenocarcinoma with double mutation of G719C and L861Q, the first case on our literature review, and showing partial response to TKI treatment.

Keyword

Adenocarcinoma; EGFR tyrosine kinase inhibitor; Lung cancer; Mutation

MeSH Terms

Adenocarcinoma*
Carcinoma, Non-Small-Cell Lung
Exons
Humans
Lung Neoplasms
Lung*
Point Mutation
Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor
Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor